Xylem price target raised to $115 from $105 at Morgan Stanley

Morgan Stanley analyst Connor Lynagh raised the firm’s price target on Xylem to $115 from $105 and keeps an Overweight rating on the shares. Lynagh likes the potential for earnings recovery and Xylem’s international exposure, the analyst tells investors in a research note.